CLINICAL_TRIALS
trial_result
· 2013-01-03
Clinical Trial Update: Metabolic Signatures and Biomarkers in Schizophrenia [Phase 1]
Summary
A Phase 1 study from Duke University evaluating metabolic signatures and biomarkers in schizophrenia has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Duke University | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2013-01-03